Thu, Apr 17, 2014, 3:14 AM EDT - U.S. Markets open in 6 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

jan31 18 posts  |  Last Activity: Mar 24, 2014 7:46 PM Member since: May 23, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Why the sudden drop?

    by rnr_toad_46a Mar 24, 2014 11:32 AM
    jan31 jan31 Mar 24, 2014 7:46 PM Flag

    Heya, bestinvestor. I wish I could link properly. It's the main curis site, then "/" and then "Erivedge-Operable-BCC-ePoster-AAD-2014" and then ".pdf"

    I agree that the main event is the hold. I think if data had been better, it would not have gone up much (or at all on a lousy day like today). At this point, though, I wouldn't want to guess how much inertia the market adds and how much inertia the company's recent bad spell adds. (To put it charitably.)

    GLTA

  • Reply to

    Why the sudden drop?

    by rnr_toad_46a Mar 24, 2014 11:32 AM
    jan31 jan31 Mar 24, 2014 5:38 PM Flag

    combined with #$%$ biomarket, of course.

  • Reply to

    Why the sudden drop?

    by rnr_toad_46a Mar 24, 2014 11:32 AM
    jan31 jan31 Mar 24, 2014 5:28 PM Flag

    Go to the following pdf file on the Curis site: Erivedge-Operable-BCC-ePoster-AAD-2014 for the results of the phas II trial that were put up yesterday. Hence the drop today.

    "Vismodegib did not demonstrate substantial enough activity to merit further development in patients with smaller operable BCC utilizing the dosing regimens used in this study."

  • FDA should respond to Curis's letter on 427 around March 20
    Roche presents at the AAD annual meeting March 21-25: maybe a bit on vismo and operable?
    AACR is April 5-9 with Curis and Debio both having presentations

    You'd think that would be worth a little run in the next couple of weeks.

  • Reply to

    Upcoming Catalysts

    by jrtorger Dec 10, 2013 2:32 PM
    jan31 jan31 Dec 10, 2013 2:52 PM Flag

    Response letter to the hold will be sent "before the end of the year" according to Ali (read the Deutsche Biofest transcript from last week).

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Sep 9, 2013 4:26 PM Flag

    just a reminder.

  • Options are lively (Oct and Dec calls), for once. Upward move appears to have deeper support than usual.

  • Reply to

    noob question

    by erg0t250 Aug 21, 2013 11:43 PM
    jan31 jan31 Aug 22, 2013 11:53 AM Flag

    biglabowski hit the main ones. Read the corporate update on CRIS's webpage for more details, or the topic below, "2013 Anticipated Milestones" for a summary of those details.

  • Second raise this year from RBC's outperform rating on CRIS.

  • Reply to

    Fox IPO

    by johndaley404 Jul 10, 2013 9:05 AM
    jan31 jan31 Aug 9, 2013 1:06 PM Flag

    "Upon completion of the IPO, we estimate that we will own approximately 56.8% of the outstanding shares of FOX common stock, assuming no exercise of the option to purchase additional shares granted to the underwriters, or approximately 53.9%, assuming full exercise of the option granted to the underwriters."

  • Reply to

    Fox IPO

    by johndaley404 Jul 10, 2013 9:05 AM
    jan31 jan31 Aug 9, 2013 1:03 PM Flag

    Fox Factory shares surge 23% on IPO

    SAN FRANCISCO (MarketWatch) -- Shares of Fox Factory Holding Corp. FOXF +1.29% jumped on the day of their initial public offering Thursday. Shares of Fox Factory surged 23% to $18.50 in recent trading. The maker of high-performance vehicle suspension products priced just under 8.6 million shares at $15 a piece late Wednesday. Fox Factory is offering 2.9 million shares and shareholders including Compass Group Diversified Holdings LLC CODI +1.50% are offering 5.7 million. Underwriters have a 30-day option to buy an additional 1.3 million shares.

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Aug 5, 2013 4:08 PM Flag

    Good. I just don't want all of the action to be limited to google and twitter...

  • jan31 jan31 Aug 5, 2013 4:06 PM Flag

    According to the CC the delay in operable results is "logistical." The conference in early Oct has an early due date that Roche couldn't meet given they are just seeing the data for the first time this week. Then next conference is Nov and they have submitted an abstract. It sounded like they would present the data there if the abstract is accepted, and later (at the beginning of 14) if not.

    So it has, according to Curis, nothing to do with the study or the data.

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Aug 5, 2013 1:24 PM Flag

    Sorry I keep talking to myself:

    According to the CC the delay in operable results is "logistical." The conference in early Oct has an early due date that Roche couldn't meet given they are just seeing the data for the first time this week. Then next conference is Nov and they have submitted an abstract. It sounded like they would present the data there if the abstract is accepted, and later (at the beginning of 14) if not.

    So it has, according to Curis, nothing to do with the study or the data.

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Aug 3, 2013 10:51 AM Flag

    From Curis's new corporate update. Two milestones met (initiation of 427 monotherapy on ovarian and Euro approval), one milestone postponed to an irritatingly vague time window (operable BCC data pushed to 1H 2014 from October 2013). Old habits die hard. If they meet a couple more milestones, I'll be convinced that they are dying, though.

     CUDC-427 (IAP antagonist) – multiple trial initiations
    • Phase 2 Breast cancer, combination with capecitabine: 3Q 2013
    X Phase 1/2 monotherapy, emphasis on ovarian cancer: initiated in July 2013
    • Phase 2 monotherapy, indolent and aggressive lymphoma: 2H 2013
     CUDC-907 (dual PI3K and HDAC inhibitor)
    • Phase 1 trial hematologic cancer preliminary results: 4Q 2013
    • Initiation of Phase 1b solid tumor trial: 2H 2013
     Erivedge (hedgehog pathway inhibitor)
    • Launch in EU member states – royalties to Curis
    O Phase 2 operable BCC data: 1H 2014
     Debio 0932 (Hsp90 inhibitor)
    • Initiation of Phase 1/2 renal cell carcinoma study: 2H 2013
    • Results from Phase 1b monotherapy trial: 2H 2013

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Jul 25, 2013 3:51 PM Flag

    Maybe Ali will actually enforce timelines! I'd like to think this new promptness is his doing.

  • Reply to

    2013 Anticipated Milestones

    by jan31 Jul 11, 2013 10:57 AM
    jan31 jan31 Jul 25, 2013 3:11 PM Flag

    First milestone reached (on time!!):

    Curis Announces Initiation of a Clinical Trial of CUDC-427 In Advanced Malignancies

    LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced dosing of the first patient in a Phase 1 dose-escalation study of CUDC-427 that is being conducted using a continuous, twice-daily oral dosing regimen in patients with advanced and refractory solid tumors or lymphoma. This trial builds on the single agent clinical results observed in the initial Phase 1 trial of CUDC-427, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2013. The primary objectives of the current study are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of CUDC-427 using a more frequent dosing regimen. Additionally, the trial is designed to enroll up to 12 patients in an expansion cohort, which is expected to primarily include patients with ovarian and fallopian tube cancers. CUDC-427 is an oral, small molecule Smac mimetic drug candidate that selectively antagonizes inhibitor of apoptosis (IAP) proteins in cancer cells, resulting in induction of programmed cell death...

    Google the headllne for the rest.

  • From Curis's Corporate Update, posted yesterday and presented at the JMP Healthcare conference. See Curis's website for the whole slideshow and to listen to the presentation.

     CUDC-427 (IAP antagonist) – multiple trial initiations
    • Phase 2 Breast cancer, combination with capecitabine: 3Q 2013
    • Phase 1/2 monotherapy, emphasis on ovarian cancer: July 2013
    • Phase 2 monotherapy, indolent and aggressive lymphoma: 2H 2013
     CUDC-907 (dual PI3K and HDAC inhibitor)
    • Phase 1 trial hematologic cancer readout: 4Q 2013
    • Initiation of Phase 1b solid tumor trial: 2H 2013
     Erivedge (hedgehog pathway inhibitor)
    • Approval in EU: 3Q 2013 (milestone payment to Curis)
    • Phase 2 operable BCC data: October 2013
     Debio 0932 (Hsp90 inhibitor)
    • Initiation of Phase 1/2 renal cell carcinoma study: 2H 2013
    • Presentation of HALO lung cancer trial results: 2H 2013

CRIS
2.30-0.02(-0.86%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.